RT-3: Research Overview

Full name

Modified 39-residue triple receptor agonist (research designation; corresponds to the analytical reference compound also referenced in published literature as Retatrutide)

Molecular formula

C221H343N51O66

Molecular weight

4731.39 g/mol

Sequence / class

39-residue triagonist sequence with Aib substitutions and a fatty-acid side chain modification

Receptor targets

Triple engagement of GLP-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR); all class B G-protein-coupled receptors coupled to Gαs

Research classification

Triple receptor research peptide. Note: the parent reference compound in published literature is investigational; the research-grade lyophilized reagent supplied here is for in vitro analytical use only and is not approved for any clinical application

PubChem CID

166617155

RT-3 is the PūrTONIX research designation for a 39-residue triagonist peptide whose analytical reference identity in published literature corresponds to the investigational molecule commonly referenced as Retatrutide. The compound combines structural features that support engagement of three class B G-protein-coupled receptors: the GLP-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. The molecular formula is C221H343N51O66 with a calculated mass near 4731 daltons.

Published literature classifies the parent reference compound as a triple receptor agonist research peptide. Each of the three target receptors is a class B GPCR coupled to Gαs, with downstream cAMP accumulation as the proximal signaling readout in cellular reporter systems. Despite the shared coupling, the three receptor classes diverge sharply in their distal signaling cascades, gene-expression programs, and metabolic-flux readouts, which makes the triagonist a uniquely informative analytical probe in in vitro multi-receptor pharmacology research.

Research published in the peer-reviewed literature has used the parent compound as an analytical reference in studies that resolve both proximal cAMP responses and distal pathway-level readouts across the three receptor classes. Hepatocyte models with native GCGR expression are common substrates for studying the glucagon-receptor arm in isolation, while β-cell models provide context for the GLP-1R and GIPR axes.

The research-grade lyophilized form supplied as RT-3 is intended strictly for in vitro analytical use. The parent reference compound is investigational and is not FDA-approved for any therapeutic application. The research reagent supplied here is not formulated, sterilized, or characterized for human or veterinary administration and is sold solely as a laboratory analytical input.

Structure reference: Public domain chemical databases (PubChem CID 166617155).

Published in vitro applications of the parent reference compound include reporter assays in single-receptor cell lines for GLP-1R, GIPR, and GCGR, and in dual- and triple-expressing cellular systems used to characterize how the triagonist engages multiple receptor classes simultaneously. cAMP accumulation, gene-expression readouts, and metabolic-flux measurements have all appeared as published analytical endpoints.

Receptor-binding studies indicate that the triagonist produces a distinct in vitro pharmacological profile that is mechanistically separable from mono- or dual-agonist research compounds in published animal-model and cellular literature. Hepatocyte models and primary cell systems with native GCGR expression are common substrates for the GCGR-specific characterization work.

Comparative in vitro panels that include mono-agonists such as semaglutide, dual-receptor compounds, and triple-receptor research peptides allow investigators to deconvolute the contribution of each receptor axis to the overall signaling signature under matched cellular assay conditions.

• [1]A study published in Cell Metabolism (2022) examined triple GLP-1/GIP/glucagon receptor agonist biochemistry in publicly available in vitro reporter systems with comparative analytical readouts.
• [2]A study published in Nature Reviews Drug Discovery (2022) reviewed publicly available literature on multi-receptor incretin research peptides and their in vitro pharmacology.
• [3]A study published in Diabetes, Obesity and Metabolism (2023) investigated triple-receptor signaling kinetics in cellular models using long-acting investigational research peptides.

The above represents a non-exhaustive summary of publicly available research. PūrTONIX does not endorse, validate, or make claims based on any referenced study.

Published chemical property data indicate that the parent reference compound is soluble in mildly alkaline aqueous buffer and in phosphate-buffered saline at standard assay concentrations. The lyophilized peptide is stored at -20°C under inert atmosphere with reconstituted stocks held in single-use aliquots at 2-8°C for short-term in vitro use.

Reconstitution in PBS or in assay-matched buffer is standard for in vitro triple-receptor pharmacology work. Analytical characterization commonly includes reverse-phase HPLC purity analysis, electrospray mass spectrometry confirming the 39-residue sequence with intact Aib substitutions and fatty-acid side chain, and residual solvent screening per ICH Q3C.

Handling recommendations are based on published chemical property data and are intended for qualified laboratory personnel only.

Triple-receptor reporter panels are sensitive to deletion peptides and to incomplete side-chain modification chemistry. Material characterized for high chromatographic purity with documented mass-spectral identity provide the analytical baseline required for reproducible in vitro multi-receptor research.